These findings underscore the potential of the endothelial CTR1-SLC25A3 mitochondrial Cu axis as a therapeutic target for preventing atherosclerosis and other cuproptosis-related diseases, including cardiovascular disorders, cancer, and neurodegenerative diseases. Here, SLC25A3 is linked to cardiovascular disorder.